The Mall Mole’s Deep Dive: Why Arjo AB’s Insider Buying is a Shopping Spree Worth Watching

Okay, folks, grab your detective hats because we’re about to crack open a case that’s got more red flags than a Black Friday sale. Arjo AB (publ), a medical tech company, has been the scene of some serious insider buying lately, and if you ask me, it’s not just your average thrift-store haul. Chairman Johan Malmquist has been on a shopping spree, and the question is: is this a smart investment or just another case of corporate window dressing?

The Chairman’s Shopping Spree: A Pattern of Confidence or Just Noise?

Let’s start with the elephant in the room—Johan Malmquist’s shopping habits. This guy has been buying shares like it’s his job (oh wait, it is). On June 10th, he dropped SEK 3.3 million on 100,000 B shares. Then, like a true bargain hunter, he came back for more on August 20th, shelling out SEK 3.366 million for another 100,000 shares. But he didn’t stop there. On October 18th, he grabbed 50,000 shares for SEK 1.8 million, and just last month, on February 12th, 2025, he added another 50,000 shares to his collection for SEK 1,930,500. That’s a total of SEK 10.4 million in shares—enough to make even the most frugal shopper raise an eyebrow.

Now, why is this a big deal? Well, when the big boss starts buying up shares like they’re going out of style, it’s usually a sign that he sees something the rest of us don’t. Malmquist isn’t just some random investor; he’s been the Chairman since 2017 and has a serious track record in the medical tech world. He’s not the kind of guy who throws money around for fun. So, when he’s dropping millions on Arjo shares, it’s a pretty strong signal that he believes in the company’s future.

But wait, there’s more! Other insiders have been joining the party too. Ulf Grunander, an Independent Director, spent a cool kr4.0 million on shares, and there’ve been reports of multiple insiders buying stock. This isn’t just Malmquist’s solo shopping trip—it’s a full-blown insider buying frenzy. And if there’s one thing I’ve learned from my days working retail, it’s that when the people in charge start stocking up, it’s usually a good sign.

The Leadership Team: Are They Shopping for Success or Just Shopping for Themselves?

Now, let’s talk about the people behind the curtain. Malmquist isn’t just some random CEO; he’s got serious experience in the medical tech sector, having previously chaired Getinge. He’s not the kind of guy who makes impulsive decisions, so when he’s buying shares, it’s a calculated move. Right now, he owns 500,000 series B shares, which is a pretty hefty stake. That’s not pocket change—it’s a serious investment.

But let’s not forget about the CEO, Joacim Lindoff. He’s been at the helm since 2017 and even stepped in as Interim CFO in 2023. His compensation has gone up by over 20% in the past year, which, on its own, isn’t a red flag. But when you combine that with the insider buying, it’s worth keeping an eye on. Are they shopping for success, or are they just shopping for themselves? That’s the million-dollar question.

The Company’s Strategy: New Products, Pricing Power, and a Discounted Stock

Arjo isn’t just sitting around waiting for the market to love them. They’re out there hustling, launching new products and tweaking their pricing strategies to boost revenue and margins. And let’s be real—when a company is focused on growth, it’s a good sign. They’re not just sitting on their hands; they’re actively working to improve their bottom line.

But here’s the kicker: according to Pareto, Arjo’s stock is currently trading at a 54% discount compared to its sector peers. That’s like finding a designer handbag at a thrift store price. It’s a steal, and it suggests that the market might be undervaluing the company. When you combine that with the insider buying, it’s a pretty compelling case that Arjo is a hidden gem.

The AGM Moves: Share Repurchases and Shareholder-Friendly Policies

The company’s Annual General Meeting (AGM) in 2025 also gave us some interesting clues. The Board of Directors got the green light to repurchase Class B shares, which is a common way for companies to boost earnings per share and return capital to shareholders. This isn’t just some random decision—they’re serious about giving value back to investors.

And let’s not forget the support from major shareholders like Carl Bennet. When the big players are backing the stock, it’s a good sign that the market is starting to take notice. The insider buying has already given the stock price a boost, and if the company keeps delivering on its promises, we could be looking at a serious growth story.

The Bottom Line: Is Arjo AB a Buy or Just Another Shopping Spree?

So, what’s the verdict? Is Arjo AB a smart investment, or is this just another case of insiders loading up before a potential downturn? Based on the evidence, it looks like Malmquist and his team are serious about Arjo’s future. The insider buying, the strategic initiatives, and the discounted stock price all point to a company that’s poised for growth.

But let’s not get too carried away. The increase in executive compensation is worth keeping an eye on, and we’ll need to see how the company performs in the coming months. Still, the signs are promising, and if you’re looking for a potential bargain in the medical tech sector, Arjo AB might just be worth a closer look.

So, mall moles, keep your eyes peeled. This shopping spree might just be the start of something big.